Key points are not available for this paper at this time.
This cohort study compares incident and prevalent prescription rates of glucagon-like peptide-1 receptor agonists among adults with at least 1 obesity-related comorbidity and newly diagnosed cancer.
Kim et al. (2025) studied this question.